biote (BTMD) Set to Release Quarterly Earnings on Wednesday

biote (NASDAQ:BTMD) will likely be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $44.01 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.26). The firm had revenue of $44.23 million for the quarter, compared to analysts’ expectations of $46.12 million. biote had a negative return on equity of 22.33% and a net margin of 3.19%. On average, analysts expect biote to post $0.03 EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

biote Price Performance

BTMD opened at $1.13 on Tuesday. biote has a 1-year low of $1.00 and a 1-year high of $2.98. The stock has a market cap of $40.60 million, a P/E ratio of 10.27 and a beta of 1.69. The stock’s 50 day simple moving average is $1.28 and its 200 day simple moving average is $1.82.

Insider Transactions at biote

In other biote news, Chairman Marc Beer purchased 115,950 shares of biote stock in a transaction on Monday, August 10th. The shares were bought at an average price of $1.53 per share, with a total value of $177,403.50. Following the completion of the acquisition, the chairman directly owned 223,744 shares of the company’s stock, valued at approximately $342,328.32. This trade represents a 107.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 32.40% of the company’s stock.

Wall Street Analyst Weigh In

BTMD has been the topic of a number of research analyst reports. TD Cowen decreased their target price on biote from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. B. Riley Financial lowered their target price on biote from $2.00 to $1.50 and set a “neutral” rating on the stock in a report on Monday, August 10th. Finally, Weiss Ratings cut biote from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $2.50.

biote Company Profile

Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.

The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.